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Background: Of many specialized blood cells, monocytes are gaining increasing attention for their role in neoplastic
disorders. The purpose of the present investigation was to determine the expression of selected peripheral blood
monocyte surface antigens in cases of cervical, endometrial, and ovarian cancers. In addition, our aim was to validate
the diagnostic value of two artificial coefficients recently proposed for the diagnosis of gynecologic malignancies:
Neutrophil to Lymphocyte Ratio (NLR), and Multiplication of Neutrophil and Monocyte Counts (MNM).
Methods: We studied 69 white Caucasian women with histopathologic confirmation of endometrial (N = 42), cervical
(N = 13), and ovarian (N = 14) cancers. Reference Group I were women suspected of cancer but histologically nullified
(N = 20), and Group II were healthy blood donors (N = 23). Expression of CD11a, CD11b, CD11c, CD16, CD54 (ICAM-1),
CD62 L (L-selectin), CD64, and HLA-DR was measured with immunofluorescence in a flow cytometer.
Results: CD54 expression increased by ≥35.6% (p < 0.001) whilst HLA-DR decreased by ≥10.8% (p < 0.001) in all
cancer subgroups and Group I as compared to blood donors. A correlation (p < 0.05) between CD54 and CD62 L
was stronger in all cancers studied than in healthy subjects. There was no difference in the NLR values between
any of these subgroups. Moreover, we observed an increase in MNM parameter in cases of cervical and endometrial
cancer and in the Reference Group I.
Conclusions: In the studied gynecologic malignancies, CD54 expression on peripheral blood monocytes is enhanced,
indicating a higher transmigrational potential present in such patients, and HLA-DR expression diminished, indicating a
decreased readiness of the immune system to recognize foreign antigens. The more pronounced correlation for the
expression of CD54 and CD62 L in cancer suggests that monocytes uptake from the bloodstream and their local
adhesion increase the pool of tumor-associated macrophages. This study challenged the suggested credibility
and usefulness of the artificial parameters of MNM and NLR for the differential diagnosis of gynecologic malignancies.
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The immune system integrates the function of the
macroorganism in health and disease. Of many special-
ized blood cells, monocytes are gaining increasing atten-
tion for their role in neoplastic disorders for a variety of
reasons. As emphasized by Hanahan and Weinberg, the
biology of malignant tumors is heterotypic, i.e. they* Correspondence: jozwikmc@interia.pl
1Department of Gynecology and Gynecologic Oncology, Medical University
of Białystok, Skłodowskiej 24 A, 15-276 Białystok, Poland
Full list of author information is available at the end of the article
© 2015 Jozwik et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.contain not only malignant cells, but also many non-
malignant cells of immune character [1]. The latter include
tumor-associated macrophages (TAMs). By evoking local
inflammatory response and cytokine production, the innate
cells of the immune system are thought to participate in
tumor growth and the disease progression [2].
Numerous studies have indicated that an increase in
the number of TAMs in the tumor tissue is an unfavorable
predictive factor for survival in breast, prostate, ovarian
and cervical cancers [3]. Whether TAMs in the specific
clinical situation play a protective role against the hostThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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an interplay of environmental factors, the degree of TAMs
activation, current stage of tumor’s development, and
localization of TAM infiltration within the tumor mass
[4-6]. Cytokines, chemokines, and growth factors pro-
duced by the tumor influence TAMs, which in return
adapt to this coexistence with the secretion of matrix pro-
teases and growth factors, suppression of acquired im-
munity, and angiogenesis modulation [7]. Interestingly,
TAMs are known to be able to synthetize at least 3 angio-
static and 14 angiogenic factors, including angiogenin and
vascular endothelial growth factor [8]. Chemokines and
other angiogenic cytokines produced by TAMs are re-
sponsible for the locally increased density of microcircula-
tion and increased vascular permeability, stabilization of
vascular structure, chemotactic attraction of monocytes,
and increase in the infiltration of tumor by macrophages
[8]. The latter two activities associated with monocytes
and macrophages continuously sustain the inflow of blood
cells and maintain the interaction: TAMs - cancer cells.
Taking the above into consideration, the present work
was undertaken to determine the expression of selected
surface monocyte antigens (Ags) in cases of cervical,
endometrial, and ovarian cancers. The Ags under study
were: CD11a, CD11b, CD11c, CD16, CD54 (or ICAM-I),
CD62 L (or L-selectin), CD64, and HLA-DR. The se-
lection of these Ags was based on their ascribed import-
ant functions in the immune system [9-12]. Specifically,
4 Ags: CD11a, CD11b, CD54, and CD62 L were chosen
to provide insight into cellular adhesion and monocyte-
endothelial transmigration, or extravasation, and the other
4, into phagocytosis, cytotoxic reaction and presentation
of foreign Ags. In addition, our secondary aim was to val-
idate the diagnostic value of two artificial ratios recently
proposed for the diagnosis of gynecologic malignancies:
Neutrophil to Lymphocyte Ratio (NLR), and Multiplica-
tion of Neutrophil and Monocyte Counts (MNM) [13,14].
Methods
Patients
This study was conducted in accordance with the princi-
ples of the World Medical Association’s Declaration of
Helsinki, the International Conference on Harmonisa-
tion Guideline for Good Clinical Practice, and the laws
and regulations of Poland. All participants were white
Caucasians and gave their written informed consent for the
study; the Bioethics Committee of the Medical University
of Białystok having earlier approved its protocol (Opinion
No. RI-003/43/2006).
Peripheral blood from antecubital vein (10 mL) was ob-
tained from women suspected of invasive gynecologic ma-
lignancy, admitted to the Department of Gynecology and
Gynecologic Oncology, Medical University of Białystok,
from April 2006 to August 2009. Preselection covered 120patients (Figure 1). Exclusion criteria were as follows:
prior treatment with chemotherapy or hormone therapy;
receipt of any blood preparation over the period of 8 weeks
prior to study, coexistence of malignancy other than geni-
tal tract tumor (especially malignancies of blood), stage
IA1 cervical cancer (minimal microscopic stromal inva-
sion), absence in postoperative material of uterine malig-
nancy found earlier from dilation and curettage biopsy,
adenocarcinoma in polipo, histopathologic diagnosis of
ovarian borderline malignancy, administration of drugs
modulating the immune system, any apparent acute or
chronic inflammation on the body, and allergies or auto-
immune disorders.
There were two reference groups. Group I (N = 20)
consisted of women whose postoperative material was
confirmed by anatomic pathology to be cancer free. These
patients were found to have: benign ovarian tumor - in
8 cases; cervical intraepithelial neoplasia or lack of
marked cervical pathology - 5; simple endometrial
hyperplasia - 3; chronic inflammation: tuberculosis - 1,
colitis - 1, salpingitis - 1; and endometriosis - 1. Group
II (N = 23) consisted of women who were healthy blood
donors. In a detailed self-reported survey of 33 questions,
they declared that they were in good general health. All of
them were verified for being negative for hepatitis B,
hepatitis C, and HIV-1 and -2 viruses. An additional
criterion for inclusion as reference was the result of
sedimentation rate (SR) not higher than 10 mm • h−1.
Height and weight were measured using professional
scale (Lublin Scale Factory, Lublin, Poland). Body mass
index (BMI) was calculated in accordance with the gen-
erally accepted formula as the individual’s body mass
(kg) divided by the square of their height (m).
Based on menstrual patterns history, each woman was
ascribed either premenopausal, perimenopausal or post-
menopausal status.
At time of surgery, material collected was immediately
fixed in a 10% buffered formalin, embedded in paraffin
and stained with hematoxylin and eosin for light micros-
copy. The histopathologic diagnosis included histological
tumor type and grading according to the World
Health Organization staging system and Kurman et al.,
respectively [15,16]. Clinical staging was done accord-
ing to FIGO classification of uterine and cervical car-
cinomas from 2009 and of ovarian carcinomas from
1990 [17,18].
Sample collection
Blood for the study was aseptically drawn during routine
preoperative sampling, thus minimizing pain and discom-
fort for the patients. The following measurements were
made: Ag surface expression on monocytes, leukocytosis
and differential white blood cells count, C-reactive protein
(CRP) concentration, and SR.
Figure 1 Flow chart for the study.
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and full differential blood count, blood was collected
into sterile 2-mL BD Vacutainer™ K3E tubes containing
K3EDTA as anticoagulant (catalog number 367836; Bec-
ton, Dickinson and Company (BD), Plymouth, UK). To
determine the concentration of CRP, blood was collected
into sterile 4-mL BD Vacutainer™ tubes (catalog number
369032). For SR determination, blood was collected into
sterile 5-mL Seditainer BD™ tubes (catalog number 366674).
Sample analysis
The SR measurement was done by a standard reading of
precipitation of the meniscus of blood after 60 minutes.Other laboratory determinations were run on fully auto-
mated analyzers continuously maintained in readiness to
use, undergoing regular service and operated in accordance
with manufacturer’s recommendations. Full blood cell count
with differential was determined using a hematological
analyzer Pentra 80 (ABX Diagnostics, Montpellier, France).
The CRP concentration was measured using an immuno-
chemical analyzer ARCHITECT® i2000 SR from Abbott
Diagnostics (Abbott Park, IL, USA).
Monocyte surface Ag expression was studied with
the immunofluorescence method in a flow cytometer
FACSCalibur™ (Becton Dickinson, Franklin Lakes, NJ, USA)
using antibodies (Abs) from Dako Denmark A/S (Glostrup,
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CD14+monocytes showing positive expression for each of
the tested surface Ags. Thus, the first stage of the proceed-
ings was to label monocytes by staining CD14 Ags on their
surface with one of two CD14 Abs (catalog numbers: R0864
and F0844). In order to eliminate the influence of autofluo-
rescence, negative controls used isotypically appropriate
Abs (catalog numbers: X0927 and X0928). The following
fluorochrome-labeled monoclonal Abs directed against
the Ags under study were used: CD11a FITC (catalog
number: F0712), CD11b PE (catalog number: R0841),
CD11c FITC (catalog number: F0713), CD16 PE (catalog
number R 7012), CD54 FITC (catalog number: F7143),
CD62L FITC (catalog number: F7085), CD64 PE (catalog
number: R7219), HLA-DR PE (catalog number: EP-R7267).
Representative examples of a scattered cytogram of nega-
tive control and cytohistograms with log scale of positively
labeled cells from an endometrial cancer patient and a
healthy woman are presented in Figure 2.
There are two alternative forms of CD16: a transmem-
brane form alpha expressed by NK cells and monocyte-
macrophages, and a glycosylphosphatidylinositol-linked
form beta present on neutrophils [12]. In other words,
the present work determined surface monocyte expres-
sion of CD16-alpha.Calculations and statistical analysis
The ratios NLR and MNM were calculated as initially
described [13,14]: NLR - index expressed as an absolute
neutrophil to lymphocytes ratio (in 1 μL of blood);Figure 2 Immunofluorescence scattergrams from flow cytometer dem
white blood cells, B - negative control, and C - CD14+CD54+ population, al
patient from Group II (healthy women). M1 - gate set on positive cells.MNM - index obtained by multiplying neutrophil counts
per μL of blood by monocyte counts per μL of blood,
and then divide by 10,000.
The distribution of particular Ags data was verified for
its agreement with normal distribution using Shapiro-Wilk
and Lilliefors tests. This analysis proved that approximately
80% of results were consistent with the normal distribution
pattern whereas circa 20% was different from normal.
Therefore, data in absolute values are expressed as
both means ± standard deviation (SD) and medians with
minimum-maximum range. All the differences were tested
with Mann–Whitney U test. The relationships of staging
and grading with laboratory data were verified with one-
way analysis of variance (ANOVA). Verifications of other
possible relationships were performed with Spearman cor-
relation. The statistical package used was STATISTICA™
10.0 (StatSoft®, Tulsa, OK, USA). p-Value < 0.05 was con-
sidered statistically significant.Results
Of the 69 women finally included in the study group, 42
had the histopathologic diagnosis of endometrioid
adenocarcinoma of the endometrium, 13 - squamous
cell carcinoma of the cervix, and 14 - epithelial ovarian
cancer. The histological types of ovarian cancer were:
serous adenocarcinoma (N = 7), endometrioid (N = 5),
and clear cell carcinoma (N = 2). Table 1 presents the
clinical characteristics of the two reference groups and
the study group with division into cancer subgroups. As
expected, healthy blood donors forming Group II wereonstrating. A - CD14+ cells (monocytes) cluster outlined from other
l from an endometrial cancer patient. D - CD14+CD54+ population in a
Table 1 Clinical characteristics of the studied women
Clinical Data Endometrial Cancer Cervical Cancer Ovarian Cancer Group I Group II
(N = 42) (N = 13) (N = 14) (N = 20) (N = 23)
Age (years) 62.52 ± 9.81; 48.77 ± 12.94; 53.21 ± 6.68; 53.42 ± 14.51; 42.52 ± 9.18;
61.50 *** 49.00 54.00 *** 51.50 ** 45.00
(44–83) (27–66) (40–65) (24–78) (25–59)
Gravidity 2.88 ± 2.20; 1.54 ± 1.33; 2.79 ± 2.04; 2.10 ± 2.40; Insufficient data
2.50; 1.00; 2.50; 2.00;
(0–13) (0–5) (0–8) (0–10)
Parity 2.69 ± 1.96; 1.15 ± 0.90; 2.57 ± 1.74; 1.85 ± 2.06; Insufficient data
2.00; 1.00; 2.00; 2.00;
(0–12) (0–3) (0–7) (0–8)
Body mass (kg) 87.13 ± 20.56; 62.46 ± 11.21; 65.09 ± 10.21; 71.30 ± 17.34; Insufficient data
85.00 60.00 69.00 68.50
(45–130) (46–80) (48–78) (47–120)
Height (cm) 159.68 ± 6.73; 160.54 ± 5.56; 161.43 ± 4.29; 164.35 ± 5.11; Insufficient data
160.00 162.00 160.00 164.00
(135–172) (152–172) (157–170) (156–174)
BMI (kg • (m2)-1) 34.14 ± 7.82; 24.38 ± 4.99; 24.97 ± 3.81; 26.37 ± 6.20; Insufficient data
31.94 22.77 26.43 24.86
(20.31-50.78) (15.55-33.73) (18.28-28.92) (18.83-4.62)
Percentage of subjects
after menopause (%)
90.48 *** 46.15 71.43 ** 60.00 * 26.09
Group I - women operated but had no malignancy in postoperative histopathologic examination, Group II - healthy women. BMI - Body Mass Index. Data are shown as:
mean ± 1 SD, median (minimum-maximum). Asterisks indicate statistically significant differences in Mann–Whitney U test: * - p < 0.05; ** - p < 0.01; *** - p < 0.001,
in comparison to Group II.
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after menopause. On the average, endometrial cancer
patients were obese.
Breakdown by stage for endometrial cancer i.e.: 61.9%
(n = 26) stage I, 19.0% (n = 8) stage II, 16.7% (n = 7) stage
III, and 2.4% (n =1) stage IV. Cervical cancer was: 38.5%
(n = 5) stage IA2, 30.8% (n = 4) stage IB, and 15.4%
(n = 2) stage IIA (2 patients were transfered to another
oncological center). Ovarian cancer was: 21.4% (n = 3)
stage II, 64.3% (n = 9) stage III, and 14.3% (n = 2) stage IV.
Endometrial cancer grading was: 14.3% (n = 6) G1, 69.0%
(n = 29) G2, and 16.7% (n = 7) G3. Cervical cancer grading
was: 7.7% (n = 1) G1, 46.2% (n = 6) G2, and 15.4% (n = 2)
G3 (in 4 cases, no grading was provided). Ovarian cancer
grading was: 28.6% (n = 4) G1, 42.9% (n = 6) G2, and
28.6% (n = 4) G3.
Table 2 presents data on the expression of the 8 selected
monocyte surface Ags. Two clear-cut observations were
made: CD54 expression was significantly increased by ≥
35.6% (p < 0.001) and HLA-DR expression was decreased
by ≥ 10.8% (p < 0.001) in all the cancer subgroups and
women operated for benign conditions as compared to
healthy blood donors. For CD11a, CD11b, CD11c, andCD64, there was no particular pattern of change in the ex-
pression in health and disease.
Table 3 presents interrelationships between these sur-
face Ags. For endometrial and ovarian cancers, there
was a correlation for CD11a and CD54, but not for
CD11b and CD54. The correlation between CD11b and
CD64 was significant for endometrial and cervical can-
cers coupled with healthy blood donors. The correlation
between CD54 and CD62 L was statistically important
for all the cancer subgroups and healthy women.
In the endometrial cancer group (n = 42), in Mann–
Whitney U test, the expression of HLA-DR in cases of
stage I (median 82.82%) differed significantly (p = 0.0055)
from the expression for stage II (median 93.00%; not
significant in comparison with other stages). The expres-
sion of HLA-DR correlated directly with staging (r = 0.3613,
p = 0.0188) and grading (r = 0.3864, p = 0.0126), and in-
versely with CRP (r = −0.4092, p = 0.0079).
Table 4 presents data on SR, CRP concentration, and
white blood cell counts and integrates them with the cal-
culated coefficients: NLR and MNM. SR was increased
(p < 0.05) in all the cancer subgroups as compared to
healthy blood donors, and CRP was increased (p < 0.01)
Table 2 Expression of surface antigens on peripheral blood monocytes in the studied women
Laboratory Data Endometrial Cancer (N = 42) Cervical Cancer (N = 13) Ovarian Cancer (N = 14) Group I (N = 20) Group II (N = 23)
CD11a (%) 99.98 ± 0.06; 99.94 ± 0.21; 99.44 ± 1.94; 99.99 ± 0.05; 99.96 ± 0.09;
100.00 100.00 100.00 100.00 100.00
(99.74-100.00) (99.23-100.00) (92.72-100.00) (99.79-100.00) (99.59 -100.00)
CD11b (%) 99.72 ± 0.73; 99.35 ± 1.60; 99.87 ± 0.16; 99.72 ± 0.45; 99.91 ± 0.16;
99.87 * 99.86 * 99.93 99.93 * 100.00
(95.28-100.00) (94.08-100.00) (99.40-100.00) (98.07-100.00) (99.47-100.00)
CD11c (%) 99.54 ± 1.36; 97.62 ± 6.74; 98.27 ± 5.87; 99.77 ± 0.37; 99.40 ± 2.37;
100.00 99.93 100.00 99.96 100.00
(92.49-100.00) 75.38-100.00) (77.93-100.00) (98.91-100.00) (88.63-100.00)
CD16 (%) 17.86 ± 22.51; 11.99 ± 18.09; 26.19 ± 31.96; 16.99 ± 26.21; 10.64 ± 4.95;
7.19 6.16 * 8.84 6.37 ** 9.55
(2.39-83.80) (1.23-69.87) (4.24-91.53) (2.78-85.20) (5.23-28.30)
CD54 (%) 83.89 ± 16.44; 87.27 ± 12.32; 89.86 ± 11.94; 92.40 ± 9.16; 63.82 ± 15.21;
88.46 *** 91.46 *** 94.57 *** 97.00 *** 65.20
(27.75-100.00) (68.40-100.00) (63.90-100.00) (69.87-100.00) (21.61-91.75)
CD62L (%) 97.64 ± 2.06; 96.51 ± 4.99; 98.80 ± 1.51; 93.69 ± 9.74; 96.56 ± 2.83;
98.35 97.85 99.18 *** 98.23 97.01
(93.00-100.00) (80.38-99.54) (94.74-100.00) (67.94-99.86) (85.40-99.70)
CD64 (%) 95.57 ± 9.06; 93.38 ± 7.42; 97.88 ± 4.67; 96.80 ± 5.22; 99.39 ± 1.19;
99.16 *** 96.30 ** 99.65 99.59 * 99.91
(47.60-100.00) (76.60-100.00) (82.13-100.00) (81.93-100.00) (95.15-100.00)
HLA-DR (%) 80.94 ± 15.85; 68.50 ± 25.66; 73.98 ± 16.60; 70.22 ± 24.76; 94.98 ± 5.66;
85.80 *** 76.60 *** 73.35 *** 79.70 *** 96.10
(33.13-99.71) (18.50-95.83) (27.65-95.21) (17.33-99.37) (73.48-99.63)
Group I - women operated but had no malignancy in postoperative histopathologic examination, Group II - healthy women. SD - standard deviation, CD - cluster
of differentiation molecule, HLA-DR - membrane receptor: Human leukocyte antigen-DR (product of hla-dr locus). Data are presented as: mean ± 1 SD, median
(minimum-maximum). Asterisks indicate statistically significant differences in Mann–Whitney U test: * - p < 0.05; ** - p < 0.01; *** - p < 0.001, in comparison to
Group II.
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from these studies showed that there was no difference
in the NLR values between any of these subgroups.
Moreover, we observed an increase in MNM parameter
not only in cases of cervical cancer (p = 0.0057), but also
in cases of endometrial cancer (p < 0.0001) and in Group
I (p = 0.0077). Another important finding from Table 4
was that the monocyte count markedly rose (p < 0.001)
in cases of endometrial and ovarian cancers in compari-
son to healthy blood donors. In other words, the pool of
monocytes available for becoming TAMs increased in
these patients.
As for the hormonal status, there were no perimeno-
pausal subjects. The analysis of the impact of hormonal
status on monocyte Ags expression suggested that post-
menopausal women with cervical cancer demonstrate a
higher HLA-DR expression than premenopausal women
(p = 0.0537; Figure 3). No further impact of gravidity,
parity, height, weight, BMI, SR, CRP, NLR, MNM, andovarian cancer histologic types on the examined Ags
was confirmed.
Discussion
When monocytes present in the bloodstream transmi-
grate through the vessel wall into the tissue, they are
known as macrophages. Similarly, when the migration
occurs into a tumor, such monocytes are labeled TAMs.
So far, there is no evidence that the processes of trans-
migration and colonization within the neoplasm result
in immediate changes of the TAMs’ surface antigenicity.
With this assumption, studies of the expression of sur-
face Ags on monocytes derived from peripheral blood
may shed light on the interplay of tissue macrophages
with other cells, including neoplastic cells.
To date, this topic has not systematically been explored
in cases of gynecologic malignancies. In 1989, De Jaco
et al. reported briefly on a small group of gynecologic can-
cer patients in whom plasma levels of CD16 increased
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Group I - women operated but had no malignancy in postoperative histopathologic examination, Group II - healthy women. r - Spearman correlation coefficient.
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et al. reported that CD16 expression on blood monocytes
in 12 endometrial cancer patients was not significantly dif-
ferent from that observed in 10 controls [20].
The present study is the ever first systematic investiga-
tion undertaken on peripheral blood monocytes Ags in
endometrial and cervical cancers and adds to the limited
existing knowledge of ovarian cancer. Its principal find-
ing is that CD54 expression is enhanced, whereas HLA-
DR expression is diminished (Table 2). Thus, the CD54
molecule which facilitates leukocyte-endothelial transmi-
gration is more abundant on monocytes, while the
HLA-DR molecule responsible for the presentation of
foreign peptide Ags to the immune system is less. The
first finding indicates a higher transmigrational potential
present in our cancer patients. The second finding can
be interpreted as a decreased readiness of the immune
system to recognize cancer cells. In their recent com-
mentary, Scarlett and Conejo-Garcia argued that the cru-
cial event driving aggressive malignant ovarian expansion
is leukocyte-mediated immunosuppression, rather than
loss of recognizable tumor antigens [21]. Our data on the
decreased monocyte HLA-DR expression in cancer sug-
gest that the diminished recognition of foreign antigenscould be a viable option. In fact, in 2006, Gordon and
Freedman demonstrated a defective Ab-dependent cyto-
toxicity and phagocytic function of human epithelial ovar-
ian cancer-associated monocytes [22]. In comparison to
normal blood monocytes, ascitic monocytes and blood
monocytes of ovarian cancer patients exhibit decreased
migration in response to chemokine ligands [23]. This is
further supported by data of Loercher et al. who identified
a subset of interleukin-10-producing HLA-DR-negative
monocytes from ascites of ovarian cancer patients that
inhibited T cells proliferation [24]. This would also be in
line with a slightly but significantly decreased expression
of CD64 (which is involved in phagocytosis and cytotoxic
reaction) in our endometrial and cervical cancer patients.
The correlation for the expression of adhesion molecules
CD54 and CD62 L was more pronounced for all cancers
studied than in healthy controls (Table 3), suggesting that
the uptake of macrophages from the bloodstream and
their local adhesion increase the pool of TAMs in the
tumor. Recently, increase in CD54 expression on colorec-
tal and pancreatic cancer cells has been shown to promote
adhesion to the senescent peritoneal mesothelium [25].
CD54 mediates the initial capture of melanoma cells by
polymorphonuclear leukocytes [26]. We observed a
Figure 3 Expression of monocyte HLA-DR surface antigen in the
studied women according to their hormonal status. Group I - women
operated but had no malignancy in postoperative histopathologic
examination, Group II - healthy women. Circles and squares represent
means, bars represent 95% confidence intervals. For cervical cancer,
the difference between premenopausal and postmenopausal women
was of borderline significance (p = 0.0537).
Table 4 Laboratory data, together with the calculated NLR and MNM coefficients, for the studied women
Parameter Endometrial Cancer (N = 42) Cervical Cancer (N = 13) Ovarian Cancer (N = 14) Group I (N = 20) Group II (N = 23)
SR (mm • h-1) 20.47 ± 14.11; 16.58 ± 16.81; 23.58 ± 12.94; 17.60 ± 20.24; 7.39 ± 1.70;
18.00 *** 12.00 * 21.00 *** 9.00 8.00
(2–59) (2–62) (5–40) (2–70) (4–10)
CRP (mg • L-1) 9.63 ± 19.16; 4.48 ± 8.68; 60.06 ± 62.42; 9.59 ± 18.94; 1.63 ± 0.85;
3.60 0.00 ** 34.00 *** 0.00 1.50
(0.00-96.30) (0.00-23.30) (0.00-204.00) (0.00-78.50) (0.50-4.00)
Leukocytosis (103 • μL-1) 7.94 ± 2.42; 8.64 ± 2.48; 7.16 ± 2.09; 7.02 ± 1.76; 6.10 ± 1.30;
7.80 ** 8.35 ** 6.90 7.41 * 6.30
(3.80-14.40) (5.30-13.30) (4.20-11.40) (4.10-11.01) (4.50-8.50)
Neutrophils (%) 57.40 ± 5.44; 61.38 ± 9.83; 58.21 ± 5.45; 52.64 ± 7.49; 57.39 ± 5.90;
57.00 62.10 57.50 54.35 56.90
(26.00-78.50) (29.30-84.60) (48.70-69.80) (38.00-75.70) (47.60-69.70)
Lymphocytes (%) 31.51 ± 5.31; 29.33 ± 9.64; 30.66 ± 5.15; 36.80 ± 6.92; 32.33 ± 6.20;
30.95 27.10 31.60 35.40 32.80
(12.00-58.50) (9.40-63.10) (17.40-41.60) (11.30-51.80) (20.30-45.00)
Monocytes (%) 8.12 ± 1.46; 7.09 ± 1.35; 7.87 ± 1.45; 9.14 ± 1.87; 6.46 ± 0.76;
7.95 *** 7.10 7.70 *** 8.60 *** 6.60
(4.80-13.10) (4.70-9.50) (5.00-10.90) (6.20-14.10) (4.70-9.60)
NLR (no titer) 2.00 ± 0.92; 2.85 ± 2.19; 2.05 ± 0.76; 1.69 ± 1.25; 1.91 ± 0.67;
1.82 2.31 1.84 1.65 1.77
(0.44-6.54) (0.46-9.00) (1.17-4.01) (0.73-6.70) (1.06-3.43)
MNM (no titer) 3.11 ± 2.00; 3.04 ± 2.12; 2.44 ± 1.73; 2.62 ± 1.79; 1.43 ± 0.61;
2.80 *** 2.30 ** 1.92 2.48 ** 1.42
(0.41-11.07) (0.00-7.63) (0.00-6.30) (0.63-7.90) (0.57-2.41)
Group I - women operated but had no malignancy in postoperative histopathologic examination, Group II - healthy women. SD - standard deviation, SR - sedimentation
rate, CRP - C-Reactive Protein, NLR - Neutrophil to Lymphocyte Ratio, MNM - Multiplication of Neutrophil and Monocyte Counts. Data are presented as: mean ± 1 SD, median
(minimum-maximum). Asterisks indicate statistically significant differences in Mann–Whitney U test: * - p < 0.05; ** - p < 0.01; *** - p < 0.001, in comparison to Group II.
Jóźwik et al. BMC Cancer  (2015) 15:129 Page 8 of 10pronounced rise in CD54 expression for our studied
cancers. For ovarian cancer in particular, this could
relate to its facilitated ability to metastasize to the
peritoneum, provided similar mechanisms promoting
CD54 expression on both monocytes and neoplastic
cells exist. Recent studies of mucin 2 molecule ex-
pression by human ovarian cancer cells revealed that
it induces local prostaglandin PGE2 synthesis in both
TAMs and cancer cells and the maintenance of a
positive feedback between PGE2 synthesis and TAM
polarization into clinically unbeneficial phenotype M2
accelerates cancer progression [27].
It is thought that CD54 function can be mediated via
activated CD18 integrins: CD11a or CD11b [9]. From
our results (Table 3), CD54 function in endometrial and
ovarian cancers appears to mediate via integrin CD11a,
but not CD11b.
As for NLR and MNM, there was no difference in the
NLR values between any subgroups (Table 4), which has
given rise to question the validity and credibility for the
usefulness of this parameter, despite the limited number
Jóźwik et al. BMC Cancer  (2015) 15:129 Page 9 of 10of observations. We confirm an increase in MNM par-
ameter in the case of cervical cancer [14]. However, we
also found MNM increases in endometrial cancer and in
the Group I. The lack of MNM selectivity for cervical
cancer disproves the credibility of this parameter in the
diagnosis of specific gynecologic cancers. Furthermore,
the 8 studied Ag molecules do not distinguish patients
with gynecologic malignancies from healthy subjects,
nor from benign gynecologic conditions.
We acknowledge the limitations of our study due to in-
sufficient clinical data from healthy blood donors (which
might affect our conclusions) and a limited number of ob-
servations on cervical cancer patients. Nonetheless, for
the endometrial and ovarian cancer patients, we were able
to demonstrate 3 simultaneous findings pointing to the
biologically important phenomenon of enhanced transmi-
gration: increased monocyte count, increased expression
of monocyte CD54 Ag, and its significant correlation with
the expression of another molecule participating in the
transmigration, CD62 L.
Further studies on the roles of monocyte surface Ags
CD54 and HLA-DR in gynecologic malignancy are
warranted.Conclusions
In summary, our study demonstrated that, in cases of
endometrial, cervical, and ovarian cancer, CD54 expres-
sion on peripheral blood monocytes is enhanced and
HLA-DR expression diminished. These observations in-
dicate both a higher transmigrational potential present
in such patients and a decreased readiness of their im-
mune system to recognize foreign antigens. This study
strongly challenged the suggested credibility and useful-
ness of the artificial parameters of MNM and NLR for
the differential diagnosis of gynecologic malignancies.
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